At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 27, 2026 at 07:33 ET
Bicara Therapeutics Inc. filed a definitive proxy statement for a shareholder vote on director elections, executive compensation, and other corporate governance matters. The filing is routine and does not contain any material financial or strategic changes.
- Filing is a DEFA14A, which is a definitive proxy statement for a shareholder meeting
- No activist campaign or contested vote is indicated
- Filing contains standard corporate governance items: director elections, executive compensation, auditor ratification
- No financial figures or strategic changes are disclosed in the filing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access